Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Australia ETF (EWA) vs Zoetis Inc (ZTS) Price & Performance

iShares MSCI Australia ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Australia ETF vs Zoetis Inc — how do they compare? iShares MSCI Australia ETF trades at $28.59 (market cap $1.17B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 25.8× iShares MSCI Australia ETF's market cap, and Zoetis Inc pays a 2.9% dividend while iShares MSCI Australia ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Zoetis Inc for 70 Days on average.

EWAZTS
Market Cap
$1.17B$30.20B
Volume
2,121,2316,175,327
Sector
Broad Market / FactorHealth
52-Week High
$30.43$147.53
52-Week Low
$24.95$69.09
Typical Hold Time
61 Days70 Days
Enterprise Value
—$37.76B
Dividend Yield
—2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Australia ETF

EWA, the iShares MSCI Australia ETF, trades at $28.56, up 1.17% today, but technical indicators are bearish with all moving averages signaling sell. The ETF provides exposure to Australian equities, heavily weighted toward commodities and financials. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns due to rising oil prices.

The outlook remains cautious amid bearish technicals and macroeconomic headwinds, though some analysts see upside potential from commodity strength. Risks include persistent inflation, tight monetary policy, and reliance on raw material exports. Investors should weigh technical weakness against long-term commodity-driven growth prospects.

Zoetis Inc

Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.

The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWA
100% Buy0% Sell
Avg holding period · 61 Days
ZTS

No sentiment data available yet.

About iShares MSCI Australia ETF

EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.

Read more on EWA →

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS →